SG Americas Securities LLC Acquires 11,407 Shares of Tandem Diabetes Care, Inc. $TNDM

SG Americas Securities LLC lifted its holdings in shares of Tandem Diabetes Care, Inc. (NASDAQ:TNDM) by 69.8% during the 2nd quarter, Holdings Channel reports. The firm owned 27,760 shares of the medical device company’s stock after purchasing an additional 11,407 shares during the quarter. SG Americas Securities LLC’s holdings in Tandem Diabetes Care were worth $517,000 at the end of the most recent quarter.

Several other large investors have also added to or reduced their stakes in the business. Assetmark Inc. lifted its stake in Tandem Diabetes Care by 42.9% in the first quarter. Assetmark Inc. now owns 1,750 shares of the medical device company’s stock valued at $34,000 after buying an additional 525 shares during the period. CWM LLC increased its stake in shares of Tandem Diabetes Care by 262.6% in the 2nd quarter. CWM LLC now owns 2,796 shares of the medical device company’s stock valued at $52,000 after acquiring an additional 2,025 shares in the last quarter. Brooklyn Investment Group lifted its position in shares of Tandem Diabetes Care by 417.8% during the 1st quarter. Brooklyn Investment Group now owns 3,397 shares of the medical device company’s stock valued at $65,000 after acquiring an additional 2,741 shares during the period. Nisa Investment Advisors LLC boosted its stake in Tandem Diabetes Care by 186.9% during the second quarter. Nisa Investment Advisors LLC now owns 4,171 shares of the medical device company’s stock worth $78,000 after acquiring an additional 2,717 shares in the last quarter. Finally, State of Wyoming grew its holdings in Tandem Diabetes Care by 49.1% in the first quarter. State of Wyoming now owns 4,467 shares of the medical device company’s stock worth $86,000 after purchasing an additional 1,471 shares during the period.

Tandem Diabetes Care Stock Performance

Shares of Tandem Diabetes Care stock opened at $20.73 on Thursday. The company has a market cap of $1.41 billion, a PE ratio of -6.80 and a beta of 1.51. Tandem Diabetes Care, Inc. has a 52 week low of $9.98 and a 52 week high of $38.28. The business has a 50 day moving average price of $15.42 and a 200-day moving average price of $16.15. The company has a quick ratio of 1.90, a current ratio of 2.44 and a debt-to-equity ratio of 2.33.

Tandem Diabetes Care (NASDAQ:TNDM) last announced its earnings results on Thursday, November 6th. The medical device company reported ($0.31) earnings per share (EPS) for the quarter, meeting the consensus estimate of ($0.31). Tandem Diabetes Care had a negative return on equity of 73.97% and a negative net margin of 20.19%.The company had revenue of $249.25 million for the quarter, compared to analysts’ expectations of $235.80 million. During the same quarter in the previous year, the firm earned ($0.35) earnings per share. Tandem Diabetes Care’s quarterly revenue was up 2.2% on a year-over-year basis. Tandem Diabetes Care has set its FY 2025 guidance at EPS. Equities analysts anticipate that Tandem Diabetes Care, Inc. will post -1.68 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of research firms have recently issued reports on TNDM. Weiss Ratings reissued a “sell (e+)” rating on shares of Tandem Diabetes Care in a research report on Wednesday, October 8th. Morgan Stanley increased their price target on Tandem Diabetes Care from $13.00 to $17.00 and gave the stock an “equal weight” rating in a report on Monday, November 10th. Royal Bank Of Canada reduced their price objective on Tandem Diabetes Care from $45.00 to $25.00 and set an “outperform” rating for the company in a research note on Thursday, August 7th. Piper Sandler lowered Tandem Diabetes Care from an “overweight” rating to a “neutral” rating and lowered their target price for the stock from $30.00 to $14.00 in a research report on Thursday, August 7th. Finally, Barclays increased their target price on Tandem Diabetes Care from $51.00 to $55.00 and gave the stock an “overweight” rating in a report on Monday, November 10th. Four investment analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, Tandem Diabetes Care presently has an average rating of “Hold” and an average target price of $21.25.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.